Compare Delta Air Lines, Inc. (DAL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Sana Biotechnology Inc — how do they compare? Delta Air Lines, Inc. trades at $89.62 (market cap $59.46B), while Sana Biotechnology Inc trades at $3.82 (market cap $1.13B). The key difference: Delta Air Lines, Inc. is far larger — about 52.6× Sana Biotechnology Inc's market cap, and Delta Air Lines, Inc. pays a 0.86% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DAL | SANA | |
|---|---|---|
Market Cap | $59.46B | $1.13B |
Sector | Industrials | Health |
52-Week High | $93.66 | $5.92 |
52-Week Low | $55.65 | $2.68 |
Enterprise Value | $74.77B | $1.05B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $89.70, up 0.55% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $1.56 versus $1.49 expected, maintaining a consistent earnings beat streak. Revenue growth has accelerated from $50.6B in 2022 to $63.4B in 2025, while net income improved to $5.0B. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $108.27 price target representing 21% upside potential.
DAL presents compelling value with attractive valuation multiples (P/E 14.99, P/S 0.87) and strong profitability metrics (ROE 20.12%). Key risks include fuel cost volatility and competitive pressure, but the company's premium travel positioning and American Express partnership provide competitive advantages. The technical setup suggests continued upward momentum with support at $88-90 levels.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
